The Lancet in conversation with

Episoade

• 
  What’s the story with mRNA vaccines? 31.07.2026 23min

  What are mRNA vaccine, how do they work, and how might they be used for in the future? And why is there a gap between the evidence and some people’s perception of their safety and efficacy? Niall Boyce from The Lancet talks to Anna Blakney, biomedical engineer and one of the authors of new Review paper "Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective". Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00512-X/abstract
• 
  What are cardiometabolic long-term conditions? 10.07.2026 19min

  What are cardiometabolic long-term conditions? To mark the publication of a new Lancet Series, editors Niall Boyce and Flávia Geraldes talk to Professor Kamlesh Khunti of the University of Leicester. They learn about a new way of conceptualising common medical conditions that has the potential to radically transform both health services and patient outcomes. Click here to read the full series: https://www.thelancet.com/series-do/lancet-series-cardiometabolic-multiple-long-term-conditions
• 
  Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology 31.05.2026 32min

  In this episode of The Lancet In Conversation With, editors Niall Boyce and Bea Gómez Pérez-Nievas are joined by three leading researchers to discuss highlights from The Lancet's special issue on neurology. The conversation covers three landmark studies: the PADOVA trial of prasinezumab in early-stage Parkinson's disease, the ORATORIO-HAND study extending ocrelizumab treatment to wheelchair-using patients with progressivemultiple sclerosis, and the HEAD study comparing tau PET tracers in Alzheimer's disease — each representing a significant step forward in the field. The guests also reflect on the broader forces reshaping neurology: the push toward earlier, biomarker-guided intervention, cross-specialty learning between the multiple sclerosis, Alzheimer's, and Parkinson's fields, and emerging platforms such as CAR T-cell therapies and blood-based biomarkers. From the transformative success of spinal muscular atrophy treatment to the prospect of an EBV vaccine preventing MS, the discussion strikes a note of cautious optimism about a specialty that is entering a new therapeutic era. Visit the lancet.com to discover more
• 
  Paul Spiegel: rethinking the humanitarian response to conflict and forced displacement 19.05.2026 31min

  Do we need to rethink our response to conflict and forced displacement? A new Lancet Commission radically rethinks policy, funding, and practical approaches to humanitarian crises. Chair Professor Paul Spiegel joins Niall Boyce from the Lancet to discuss the aims and recommendations of this Commission on one of the most pressing health issues of the 21st century. Click here to visit the commission page and read the full article: www.thelancet.com/commissions-do/conflict-forced-displacement   
• 
  Can semaglutide be used to treat alcohol use disorder? 02.05.2026 31min

  The Lancet’s Niall Boyce and Jonathan Pimm, and eBioMedicine’s Kalypso Karastergiou discuss an exciting new potential treatment for alcohol use disorder: semaglutide. As new research is published in The Lancet, they go behind the headlines with lead author Professor Anders Fink-Jensen to ask what the study showed, and what its implications are for the future of addiction medicine. Click here to read the full article:  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext
• 
  Louise Chappell and Na’ama Carlin on Personal Cancer Stories 03.02.2026 30min

  The uniqueness of each patient is at the heart of this year's World Cancer Day. Each cancer patient has their own hopes, dreams and fears. In this Podcast you will hear from two cancer survivors about their unique experience with cancer and the importance of personalised cancer care not only on their bodies but also on their lives. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedic...
• 
  Susannah Stanway on the London Global Cancer Week 19.12.2025 24min

  In Conversation with The Lancet returns with Dr Susannah Stanway, honorary consultant medical oncologist at the Royal Marsden and honorary clinical senior lecturer in Education at the Institute of Cancer Research, reflecting on London Global Cancer Week 2025. This episode goes beyond event highlights to discuss the need for a global oncology agenda rooted in equity, evidence-based care, and value across care settings. Topics span from geriatric oncology to cardio-oncology, nursing workforce r...
• 
  Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health 09.12.2025 1h 1min

  Ultra-processed foods are on the rise. Despite the emphasis placed on individual responsibility, our deteriorating diets are primarily the result of the sophisticated political tactics of a powerful global ultra-processed food industry. Addressing this urgent threat demands a coordinated response from the global public health community. So argues a 3-paper Series published in The Lancet that examines the evidence, proposes policies to halt and reverse the rise in ultra-processed foods, and il...
• 
  Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma 07.12.2025 13min

  Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thela...
• 
  Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC 19.10.2025 20min

  Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
• 
  Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer 17.10.2025 22min

  Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
• 
  Stephen Chan on the Lancet Commission on addressing the global hepatocellular carcinoma burden 28.07.2025 20min

  With the global burden of liver cancer growing, The Lancet has commissioned an international panel of experts to identify strategies to strengthen the prevention, surveillance, diagnosis, and treatment of liver cancer. Stephen Chan joins Ben Abbott of The Lancet to discuss the key messages of the Commission, which is published today on World Hepatitis Day. Read the full Commission: https://www.thelancet.com/commissions-do/hepatocellular-carcinoma?dgcid=buzzsprout_icw_podcast_lancethcc25_lance...
• 
  Rebecca Fitzgerald on biomarker risk stratification with capsule sponge in the surveillance of Barrett’s oesophagus 24.07.2025 27min

  Early detection of oesophageal adenocarcinoma improves outcomes. Patients with the precursor lesion, Barrett's oesophagus, are recommended to undergo regular endoscopic surveillance, a process that can be burdensome for patients and health services. Professor Rebecca Fitzgerald's team have developed a tool that may be able to improve Barrett's surveillance. She joins us to discuss her recent prospective real-world implementation study of capsule sponge risk stratification in Barrett’s o...
• 
  ASCO 2025 Debrief 11.06.2025 14min

  Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, and Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167 Articles discussed in this podcast episo...
• 
  Presented at ASCO: the first RCT of CAR T-cell therapy in solid tumours 31.05.2025 14min

  Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lancet Continue this conversation on social! Follow us today at... https://thel...
• 
  Previewing ASCO 2025 30.05.2025 4min

  Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, joins Gavin Cleaver to discuss what's being published at this year's American Society of Clinical Oncology (ASCO) meeting, what she's excited to see at the conference, and why ASCO is so important to the field. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/c...
• 
  Francis Couturaud on treatment of venous thromboembolism 14.03.2025 28min

  Francis Couturaud joins Chloe Wilson of The Lancet to discuss the RENOVE trial, which looks at assessing the efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated. Read the full paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02842-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.socia...
• 
  Shawn St Peter on appendicectomy versus antibiotics for acute uncomplicated appendicitis in children 27.01.2025 16min

  This week, we discuss treatment approaches for uncomplicated appendicitis in children following the publication of a trial in our January 18th issue. Lead author Shawn St Peter, general paediatric surgeon and surgeon-in-chief at Children’s Mercy Hospital, Kansas City, spoke with Callam Davidson about the motivation behind the study, key findings, and what the results mean for clinical practice. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02420-6/...
• 
  Michael Heneka on passive anti-amyloid β immunotherapy in Alzheimer’s disease 09.01.2025 21min

  Michael Heneka joins Chloe Wilson and Bea Gomez Perez-Nievas of The Lancet to discuss a therapeutics paper discussing the opportunities and challenges of passive anti-amyloid β immunotherapy in Alzheimer's disease. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01883-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup ht...
• 
  Nusrat Husain, Farah Lunat, and Fehmida Motala on postnatal depression in British south Asian women (the ROSHNI-2 trial) 31.10.2024 48min

  ROSHNI-2 was a multicentre, randomised controlled trial that investigated the efficacy of a culturally adapted, cognitive behavioural therapy-based intervention for postnatal depression in British south Asian women. Joining us to share their expertise and perspectives are chief investigator Professor Nusrat Husain, trial manager Farah Lunat, and service user representative Fehmida Motala. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01612-X/fullte...